The Cocktail Report (sound really smart around your friends):
Researchers traced a chain of signals linking marrow fat cells, immune cells, and bone-forming stem cells to age-related bone loss (Advanced Science).
STING, an immune signaling system, helped drive inflammation and disrupt supplies needed to maintain NAD+, a molecule that helps cells use energy and repair damage (Advanced Science).
A treatment combining a STING-blocking drug with NMN, a building block for NAD+, improved bone density and internal bone structure in aging mice (Advanced Science).
If concern about weak bones has made you more cautious on stairs or slippery sidewalks, you have a reason to care about this finding. Researchers have traced a process inside aging bone marrow that interferes with the cells responsible for making new bone.
The study, published October 15 in Advanced Science, connects fat accumulation in marrow with immune activity and a shortage of materials used for cellular maintenance. Its main contribution is explaining how these changes can reinforce one another.
The trouble starts between cells
The researchers found that aging marrow fat cells release a protein called DPP4, which helps activate STING in nearby macrophages, immune cells that respond to damage and infection. DNA escaping from the macrophages' mitochondria, their energy-producing structures, also contributes to that activation.
Activated STING increases production of CD38, an enzyme that breaks down molecules used in the NAD+ supply system. The proposed consequence is less NMN available to neighboring stem cells, leaving them less able to maintain NAD+ and develop into bone-building cells.
In other words, the bone-building cells are being affected by what surrounding cells release and consume. The work points to a problem in their surroundings, not simply a failure within the builders themselves.
Testing whether the chain can be interrupted
The team used several approaches to alter this pathway, including reducing STING activity in marrow macrophages. Suppressing that activity from middle age onward helped limit bone deterioration in the mice.
In a separate treatment experiment, researchers paired H-151, a drug that inhibits STING, with NMN supplementation over a six-month period. The combination improved bone density and the internal framework of bone, alongside measures of bone formation.
For your own future treatment choices, the distinction worth watching is whether a therapy helps the cells that make bone do their job. This study gives researchers a specific chain of events to investigate, rather than treating every age-related change as a separate problem.
A word of caution
STING is not simply a harmful switch: losing it earlier in life was detrimental to bone development, so age and timing matter. Most of the work used male mice, and the combination-treatment experiment had six animals per group.
The researchers did not include separate H-151-only and NMN-only groups, so this experiment cannot tell us how much each contributed. It also did not establish fewer fractures, greater mechanical bone strength, or effectiveness in people.
Why Should You Care?
This is a useful explanation of how aging can undermine bone repair, and a lead for developing treatments. I would follow the research, not use it as a reason to buy NMN or change prescribed osteoporosis treatment.
Li Z, Gao K, Wang M, et al. "Bone Marrow Macrophage STING Signaling is a Direct Nexus Linking Marrow Adipose Expansion to NAD+ Depletion and Osteogenic Decline in Skeletal Aging." Advanced Science, e77571. First published October 15, 2026. Full text, methods, figure legends, limitations, and disclosures reviewed. https://onlinelibrary.wiley.com/doi/full/10.1002/advs.77571
